Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck dB Income Statement — Consolidated Sales / Revenue ($M) ($M)
Postgres DB financial_values (via lib/db.py)
Latest, Q2 2026
16,607
Period ended Jun 30, 2026
Change on a year earlier
+5.1%
15,806 in Q2 2025
History
69 quarters
Since Q2 2008
Sources
61
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | DB Income Statement — Consolidated Sales / Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 16,607 | +5.1% | Form 10-Q (filed 2026-08-07) ↗ |
| Q1 2026 | Mar 31, 2026 | 16,286 | +4.9% | Form 10-Q (filed 2026-05-04) ↗ |
| Q4 2025 | Dec 31, 2025 | 16,400 | +5.0% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2025 | Sep 30, 2025 | 17,276 | +3.7% | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2025 | Jun 30, 2025 | 15,806 | -1.9% | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 15,529 | -1.6% | Form 10-Q (filed 2025-05-02) ↗ |
| Q4 2024 | Dec 31, 2024 | 15,624 | +6.8% | Form 10-K (filed 2025-02-25) ↗ |
| Q3 2024 | Sep 30, 2024 | 16,657 | +4.4% | Form 10-Q (filed 2024-11-06) ↗ |
| Q2 2024 | Jun 30, 2024 | 16,112 | +7.2% | Form 10-Q (filed 2024-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 15,775 | +8.9% | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2023 | Dec 31, 2023 | 14,630 | +5.8% | Form 10-K (filed 2024-02-26) ↗ |
| Q3 2023 | Sep 30, 2023 | 15,962 | +6.7% | Form 10-Q (filed 2023-11-03) ↗ |
| Q2 2023 | Jun 30, 2023 | 15,035 | +3.0% | Form 10-Q (filed 2023-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 14,487 | -8.9% | Form 10-Q (filed 2023-05-05) ↗ |
| Q4 2022 | Dec 31, 2022 | 13,830 | +2.3% | Form 10-K (filed 2023-02-24) ↗ |
| Q3 2022 | Sep 30, 2022 | 14,959 | +13.7% | Form 10-Q (filed 2022-11-03) ↗ |
| Q2 2022 | Jun 30, 2022 | 14,593 | +28.0% | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2022 | Mar 31, 2022 | 15,901 | +49.6% | Form 10-Q (filed 2022-05-05) ↗ |
| Q4 2021 | Dec 31, 2021 | 13,521 | +23.5% | Form 10-K (filed 2022-02-25) ↗ |
| Q3 2021 | Sep 30, 2021 | 13,154 | +20.4% | Form 10-Q (filed 2021-11-05) ↗ |
| Q2 2021 | Jun 30, 2021 | 11,402 | +21.9% | Form 10-Q (filed 2021-08-09) ↗ |
| Q1 2021 | Mar 31, 2021 | 10,627 | -11.9% | Form 10-Q (filed 2022-05-05) ↗ |
| Q4 2020 | Dec 31, 2020 | 10,948 | +163.9% | Form 10-K (filed 2022-02-25) ↗ |
| Q3 2020 | Sep 30, 2020 | 10,929 | -11.8% | Form 10-Q (filed 2021-11-05) ↗ |
| Q2 2020 | Jun 30, 2020 | 9,353 | -20.5% | Form 10-Q (filed 2021-08-09) ↗ |
| Q1 2020 | Mar 31, 2020 | 12,057 | +11.5% | Form 10-Q (filed 2020-05-06) ↗ |
| Q4 2019 | Dec 31, 2019 | 4,149 | -62.3% | Form 10-K (filed 2022-02-25) ↗ |
| Q3 2019 | Sep 30, 2019 | 12,397 | +14.9% | Form 10-Q (filed 2019-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 11,760 | +12.4% | Form 10-Q (filed 2019-08-06) ↗ |
| Q1 2019 | Mar 31, 2019 | 10,816 | +7.8% | Form 10-Q (filed 2019-05-08) ↗ |
| Q4 2018 | Dec 31, 2018 | 10,998 | +5.4% | Form 10-K (filed 2019-02-27) ↗ |
| Q3 2018 | Sep 30, 2018 | 10,794 | +4.5% | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2018 | Jun 30, 2018 | 10,465 | +5.4% | Form 10-Q (filed 2018-08-07) ↗ |
| Q1 2018 | Mar 31, 2018 | 10,037 | +6.4% | Form 10-Q (filed 2018-05-08) ↗ |
| Q4 2017 | Dec 31, 2017 | 10,433 | +3.1% | Form 10-K (filed 2018-02-27) ↗ |
| Q3 2017 | Sep 30, 2017 | 10,325 | -2.0% | SEC Filing ↗ |
| Q2 2017 | Jun 30, 2017 | 9,930 | +0.9% | SEC Filing ↗ |
| Q1 2017 | Mar 31, 2017 | 9,434 | +1.3% | SEC Filing ↗ |
| Q4 2016 | Dec 31, 2016 | 10,115 | -1.0% | SEC Filing ↗ |
| Q3 2016 | Sep 30, 2016 | 10,536 | +4.6% | SEC Filing ↗ |
| Q2 2016 | Jun 30, 2016 | 9,844 | +0.6% | SEC Filing ↗ |
| Q1 2016 | Mar 31, 2016 | 9,312 | -1.2% | SEC Filing ↗ |
| Q4 2015 | Dec 31, 2015 | 10,215 | -2.5% | Form 10-K (filed 2016-02-26) ↗ |
| Q3 2015 | Sep 30, 2015 | 10,073 | -4.6% | Form 10-Q (filed 2015-11-05) ↗ |
| Q2 2015 | Jun 30, 2015 | 9,785 | -10.5% | Form 10-Q (filed 2015-08-06) ↗ |
| Q1 2015 | Mar 31, 2015 | 9,425 | -8.2% | Form 10-Q (filed 2015-05-07) ↗ |
| Q4 2014 | Dec 31, 2014 | 10,482 | – | Form 10-K (filed 2015-02-27) ↗ |
| Q3 2014 | Sep 30, 2014 | 10,557 | -52.1% | Form 10-Q (filed 2014-11-10) ↗ |
| Q2 2014 | Jun 30, 2014 | 10,934 | – | Form 10-Q (filed 2014-08-07) ↗ |
| Q1 2014 | Mar 31, 2014 | 10,264 | -3.8% | Form 10-Q (filed 2014-05-08) ↗ |
| Q2 2013 | Sep 30, 2013 | 22,042 | +91.9% | Form 10-Q (filed 2013-11-07) ↗ |
| Q1 2013 | Mar 31, 2013 | 10,671 | -9.0% | Form 10-Q (filed 2013-05-09) ↗ |
| Q4 2012 | Dec 31, 2012 | 11,737 | -4.5% | Form 10-K (filed 2013-02-28) ↗ |
| Q3 2012 | Sep 30, 2012 | 11,488 | -4.4% | Form 10-Q (filed 2012-11-09) ↗ |
| Q2 2012 | Jun 30, 2012 | 12,311 | – | Form 10-Q (filed 2012-08-07) ↗ |
| Q1 2012 | Mar 31, 2012 | 11,731 | – | Form 10-Q (filed 2012-05-08) ↗ |
| Q4 2011 | Dec 31, 2011 | 12,294 | +1.7% | Form 10-K (filed 2012-02-28) ↗ |
| Q3 2011 | Sep 30, 2011 | 12,022 | +8.1% | Form 10-Q (filed 2011-11-08) ↗ |
| Q4 2010 | Dec 31, 2010 | 12,094 | +19.8% | Form 10-Q (filed 2011-11-08) ↗ |
| Q3 2010 | Sep 30, 2010 | 11,125 | +83.9% | Form 10-Q (filed 2011-11-08) ↗ |
| Q2 2010 | Jun 30, 2010 | 11,346 | +92.3% | Form 10-Q (filed 2011-08-08) ↗ |
| Q1 2010 | Mar 31, 2010 | 11,422 | +112.1% | Form 10-Q (filed 2011-05-09) ↗ |
| Q4 2009 | Dec 31, 2009 | 10,093 | +4.1% | Form 10-K (filed 2011-02-28) ↗ |
| Q3 2009 | Sep 30, 2009 | 6,050 | +32.2% | Form 10-Q (filed 2010-11-08) ↗ |
| Q2 2009 | Jun 30, 2009 | 5,900 | +19.9% | Form 10-Q (filed 2010-08-06) ↗ |
| Q1 2009 | Mar 31, 2009 | 5,385 | – | Form 10-Q (filed 2010-05-07) ↗ |
| Q4 2008 | Dec 31, 2008 | 9,696 | – | Form 10-K (filed 2011-02-28) ↗ |
| Q3 2008 | Sep 30, 2008 | 4,576 | – | Form 10-Q (filed 2009-10-29) ↗ |
| Q2 2008 | Jun 30, 2008 | 4,921 | – | Form 10-Q (filed 2009-07-24) ↗ |
Breakdown
What makes up db income statement — consolidated sales / revenue ($m)
- Cost of Sales ($M)4,395 · Q2 2026
- Selling, General and Administrative (SG&A) ($M)2,904 · Q2 2026
- Advertising Expense ($M)–
- Research and Development (R&D) ($M)9,741 · Q2 2026
- Restructuring Costs ($M)151 · Q2 2026
- Other (Income) Expense, Net ($M)-99 · Q2 2026
- Interest Income ($M)35 · Q2 2026
- Interest Expense ($M)525 · Q2 2026
- Gain (Loss) on Equity Investments ($M)242 · Q2 2026
- Income Before Taxes ($M)-683 · Q2 2026
- Taxes on Income ($M)654 · Q2 2026
- Income from Discontinued Operations, Net of Taxes (Organon Spin-Off) ($M)0 · Q4 2022
- Less: Net Income Attributable to Noncontrolling Interests ($M)-2 · Q2 2026
- Net Income Attributable to Merck & Co., Inc. ($M)-1,335 · Q2 2026
- Basic EPS ($)-0.54 · Q2 2026
- Diluted EPS ($)-0.54 · Q2 2026
- Weighted-Average Basic Shares (M)2,470.00 · Q2 2026
- Weighted-Average Diluted Shares (M)2,470.00 · Q2 2026
- Dividends Declared per Common Share ($)0.85 · Q2 2026
Cite this data
StockData. (2026). Merck DB Income Statement — Consolidated Sales / Revenue ($M) ($M), quarterly Q2 2008–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/db_inc_rev
See every metric in the Merck KPI table. Data updated Oct 26, 2026.